| Name | Title | Contact Details |
|---|
Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients. Based on an innovative scientific approach and industry leading internal manufacturing capability and expertise, we are currently exploring three gene therapy modalities: gene replacement, exon skipping gene therapy, and vectorized RNA knockdown and will also advance additional Astellas gene therapy programs toward clinical investigation. We are based in San Francisco, with manufacturing and laboratory facilities in South San Francisco and Sanford, North Carolina.
Hymed Group Corp. is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Founded in 1934, Beekley Corporation has evolved into the world leading supplier of simple innovative medical products that help imaging, surgical, and radiation therapy professionals save time, improve accuracy, enhance communication and provide a better patient experience. Beekley introduced the X-SPOT, the first ever professional skin marker for diagnostic imaging in 1984. The X-SPOT® replaced a variety of makeshift methods used at the time for communicating an area of concern on film. It quickly became a staple in radiology departments across the country and its quick adaptation in all radiology modalities led Beekley to devote itself to the research and development of simple, low cost, disposable products that would help imaging professionals improve communication, productivity, and patient care. Today, Beekley`s product line has grown to include a broad range of radiologic skin markers, biopsy and patient care devices for Mammography; Breast Biopsy; Radiation Therapy; MRI; CT-Scan and General Radiology.
timm medical technologies inc is a Eden Prairie, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Ceterix Orthopaedics is singularly focused on meniscal preservation and is dedicated to providing patients every opportunity to maintain the natural health and stability of their knee. The company develops tools that help surgeons repair many of the tears that currently remain untreated or are treated by meniscectomy (meniscus removal), a procedure associated with increased risk of arthritis or total knee replacement later in life. The Ceterix NovoStitch® Plus Meniscal Repair System provides surgeons with the unique ability to repair horizontal, radial, root and other complex tears. Based in Fremont, Calif., the company is backed by investors Novo Ventures, Versant Ventures and 5AM Ventures.